Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Multi-center, Randomized, Double-Blind, Vehicle Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

Trial Profile

A Phase 2B, Multi-center, Randomized, Double-Blind, Vehicle Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allantoin (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Sponsors Scioderm
  • Most Recent Events

    • 03 May 2016 Data from this trial will be presented at the Society of Investigative Dermatology's (SID) 2016 SID Annual Meeting, according to an Amics Therapeutics media release.
    • 26 Feb 2016 Data from this trial will be presented at the American Academy of Dermatology's Annual Meeting 2016, according to an Amicus Therapeutics media release.
    • 02 Sep 2015 According to Amicus Therapeutics media release, allantoin [SD 101; Zorblisa] has received breakthrough designation from US FDA based on phase II data.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top